Conference Cochairs:
Othon Iliopoulos, Massachusetts General Hospital, Charlestown, Massachusetts
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
Cheryl Lyn Walker, Baylor College of Medicine, Houston, Texas
Qing Zhang, UT Southwestern Medical Center, Dallas, Texas

SATURDAY, JUNE 24, 2023

Opening Plenary Session (Welcome, Keynote Talk)
5:00-7:30 p.m.

TBD
Peter J. Ratcliffe, The Francis Crick Institute, London, United Kingdom [R]

HHLA2/KIR3DL3 as a new target for kidney cancer immunotherapy
Gordon Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts

The TIL landscape of renal cell carcinoma
Catherine J. Wu, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Opening Reception
7:30-9:00 p.m.

SUNDAY, JUNE 25, 2023

Continental Breakfast with Mentoring Roundtables
7:00-8:00 a.m.

Plenary Session 1: New Therapeutic Targets in Kidney Cancer
8:00-10:00 a.m.
Session Chair: Othon Iliopoulos, Massachusetts General Hospital, Charlestown, Massachusetts

Identification of potential new therapeutic targets in kidney cancer
Qing Zhang, UT Southwestern Medical Center, Dallas, Texas

The oncogenic role and therapeutic potential of the RNA demethylase FTO in VHL deficient renal cell carcinoma
Erinn Rankin, Stanford University, Stanford, California

Adipokine signaling as therapeutically targetable metabolic regulator in clear cell Renal Cell Carcinoma
Scott M. Welford, University of Miami, Miami, Florida
A novel strategy for the induction of ferroptosis in kidney cancer through ISCA2 inhibition
Mei Yee Koh, University of Utah, Salt Lake City, Utah

Break
10:00-10:30 a.m.

Plenary Session 2: New Paradigms on Kidney Cancer Treatments
10:30 a.m.-12:30 p.m.
Session Chair: M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

TBD
Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas

Development of HIF2 inhibitors: Bench to bedside and back
James Brugarolas, UT Southwestern Medical Center, Dallas, Texas

Designing the next generation of clinical trials in renal cell carcinoma based on today’s evidence
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts

The future of systemic therapy for metastatic RCC
Brian I. Rini, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Lunch Break (lunch on your own)
12:30-2:30 p.m.

Plenary Session 3: Modeling Kidney Cancer
2:30-4:00 p.m.
Session Chair: Cheryl Lyn Walker, Baylor College of Medicine, Houston, Texas

Modelling childhood cancer using organoid technology
Jarno Drost, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Zebrafish modelling of VHL disease
Rachel Giles, University Medical Center Utrecht, Utrecht, Netherlands

Biorepository of clear cell and non-clear cell renal cell tumoroids to study unique therapeutic vulnerabilities*
Samir Zaidi, Memorial Sloan Kettering Cancer Center, New York, New York

Injury-associated transcriptional state transitions in early renal carcinogenesis*
Sakari Vanharanta, University of Helsinki, Helsinki, Finland

Break
4:00-4:30 p.m.
Hot Topics in Kidney Cancer: Proffered Talks from Highly Rated Abstracts
4:30-6:00 p.m.
Session Chairs:
Kathryn Beckermann, Vanderbilt University Medical Center, Nashville, Tennessee
Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts

PBRM1-deficient PBAF complexes target aberrant genomic loci to activate NF-κB pathway in clear cell renal cell carcinoma*
Xiaosai Yao, Genentech, South San Francisco, California

Comparative genomic analysis of novel translocation renal cell carcinoma model reveals molecular mechanisms of disease progression and therapeutic opportunities*
Gopinath Prakasam, The University of Texas Southwestern Medical Center, Dallas, Texas

An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas*
Ariel Madrigal, McGill University, Montreal, QC, Canada

STING is a vulnerability in RCC independent of its innate immunity function*
Pengda Liu, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Von Hippel Lindau (VHL) tumor suppressor regulates m6A-dependent gene expression involved in renal tumorigenesis*
Cheng Zhang, UT Southwestern Medical Center, Dallas, Texas

The SLC1A1/EAAT3 dicarboxylic amino acid transporter: An actionable, HIF-independent, hub that links epigenetic dysregulation to nucleotide metabolism in kidney cancer*
Abhishek A. Chakraborty, Cleveland Clinic, Cleveland, Ohio

Poster Session A (with light refreshments)
6:00-8:00 p.m.

MONDAY, JUNE 26, 2023

Continental Breakfast with Mentoring Roundtables
7:00-8:00 a.m.

Plenary Session 4: Targeting Epigenetics in Kidney Cancer
8:00-10:00 a.m.
Session Chair: Liling Wan, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
An AACR Special Conference in Cancer Research

Advances in Kidney Cancer Research
June 24-27, 2023 | Hyatt Regency Austin | Austin, Texas

TBD
Cheryl Lyn Walker, Baylor College of Medicine, Houston, Texas

Oncogenic transcriptional condensates in cancer: Molecular mechanism and therapeutic opportunity
Liling Wan, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania

Remodeling of tumor metabolism by L-2-hydroxyglutarate: Implications for RCC growth and progression
Sunil Sudarshan, University of Alabama at Birmingham, Birmingham, Alabama

Linking VHL and SETD2 in a common oncogenic pathway that converges on the mitotic spindle*
Ruhee Dere, Baylor College of Medicine, Houston, Texas

In-“speck”-ting the nucleus: Nuclear speckles are a critical layer of gene regulation that predict outcomes in clear cell renal cell carcinoma*
Katherine A. Alexander, University of Pennsylvania, Philadelphia, Pennsylvania

Break
10:00-10:30 a.m.

Plenary Session 5: Targeting Tumor Metabolism in Kidney Cancer
10:30 a.m.-12:30 p.m.
Session Chair: Ralph J. DeBerardinis, UT Southwestern Medical Center, Dallas, Texas

Metabolic reprogramming and kidney cancer progression in patients
Ralph J. DeBerardinis, UT Southwestern Medical Center, Dallas, Texas

Therapeutic targets of HIF-driven changes in cancer metabolism
Othon Iliopoulos, Massachusetts General Hospital, Boston, Massachusetts

Targeting metabolism in the RCC tumor microenvironment
W. Kimryn Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee

Exploiting cholesterol metabolism for treatment resistant ccRCC patients
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania

Department of Defense Kidney Cancer Research Program
12:30-1:00 p.m.
Session Chair: Theresa J. Miller, Kidney Cancer Research Program, Frederick, Maryland

Theresa J. Miller, Kidney Cancer Research Program, Frederick, Maryland
Cheryl Lyn Walker, Baylor College of Medicine, Houston, Texas
Lunch Break (lunch on your own)
1:00-3:00 p.m.

Plenary Session 6: New Genomic and Proteomic Approaches in Kidney Cancer
3:00-5:00 p.m.
Session Chair: Qing Zhang, UT Southwestern Medical Center, Dallas, Texas

TBD
- A. Ari Hakimi, Memorial Sloan Kettering Cancer Center, New York, New York

TBD
- Samra Turajlic, The Francis Crick Institute, London, England

TBD
- Daniel D. De Carvalho, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada

**Downregulation of the HIF2a target Cyclin D1 underlies the efficacy of the HIF2a inhibitor Belzutifan in kidney cancer***
- Nitin H. Shirole, Dana-Farber Cancer Institute, Boston, Massachusetts

**SETD2 safeguards the genome against isochromosome formation***
- Frank M. Mason, Vanderbilt University Medical Center, Nashville, Tennessee

Poster Session B (with light refreshments)
5:00-7:00 p.m.

TUESDAY, JUNE 27, 2023

Continental Breakfast with Mentoring Roundtables
7:00-8:00 a.m.

Plenary Session 7: Subtypes of Kidney Cancer and Therapeutic Implications
8:00-10:00 a.m.
Session Chair: Samra Turajlic, The Francis Crick Institute, London, England

**New advances in the pathogenesis of RCC in tuberous sclerosis and Birt-Hogg-Dubé***
- Elizabeth P. Henske, Harvard Medical School/Brigham and Women's Hospital, Boston, Massachusetts

**Renal medullary carcinoma: Discovery and validation of tailored treatment strategies***
- Pavlos Msaouel, UT MD Anderson Cancer Center, Houston, Texas

**Energy sensing and disease: The FLCN/mTOR/AMPK/TFE3 pathway***
- Arnim Pause, McGill University, Montreal, QC, Canada
An integrative genomics approach converges on a critical OXPHOS program driven by MiT/TFE fusions in translocation renal cell carcinoma*
Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts

Macrophage induced epithelial to mesenchymal transition in sarcomatoid renal cell carcinoma*
Allison May, University of Michigan, Ann Arbor, Michigan

Break
10:00-10:30 a.m.

Plenary Session 8: Immunotherapies and Combinational Therapies in Kidney Cancer
10:30 a.m.-12:00 p.m.
Session Chair: W. Kimryn Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee

Cardio-oncology—ICI-myocarditis: Bench to bedside
Javid J. Moslehi, UCSF School of Medicine, San Francisco, California

Non-canonical tumor antigens in RCC
William Y. Kim, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma*
David A. Braun, Yale School of Medicine, New Haven, Connecticut

Systemic T cell metabolic and effector function changes following treatment with PD1 and CTLA4 in patients with kidney cancer*
Kathryn Beckermann, Vanderbilt University Medical Center, Nashville, Tennessee

Closing Remarks
12:00-12:15 p.m.

Othon Iliopoulos, Massachusetts General Hospital, Charlestown, Massachusetts
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
Cheryl Lyn Walker, Baylor College of Medicine, Houston, Texas
Qing Zhang, UT Southwestern Medical Center, Dallas, Texas